Prothena | PRTA - Debt


Prothena reported $7.65M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amgen USD 57.32B 2.72B Mar/2026
Biogen USD 8.09B 1.53B Jun/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Exelixis USD 165.93M 3.61M Jun/2026
Immunic USD 0 0 Jun/2024
Incyte USD 38.27M 1.16M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
MacroGenics USD 36.51M 500K Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Prothena USD 7.65M 1.43M Mar/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026